UK Public Sector Contracts & Tenders

This UK3 Planned Procurement Notice is issued for information purposes only. The UK Health Security Agency (UKHSA) is not inviting responses to this notice. UKHSA recently conducted preliminary market engagement in respect of a Hydrogen Peroxide Generator for use in the Biosafety, Air and Water Microbiology Group at Porton Down. For further details please see the Preliminary Market Engagement Notice identifier 2026/S 000-064485 published on 09 July 2026. Hydrogen Peroxide Generator - Find a Tender The market engagement stage has now ended and the UKHSA intends to proceed with a below threshold open procedure. The UKHSA is responsible for planning, preventing and responding to external health threats, and providing intellectual, scientific and operational leadership at national and local level, as well as on the global stage. UKHSA ensures the nation can respond quickly and at greater scale to deal with pandemics and future threats. It does this through advocacy, partnerships, world-class science, knowledge and intelligence, and the delivery of specialist public health services. UKHSA is an operationally autonomous executive agency of the United Kingdom Department of Health and Social Care (DHSC). The UKHSA has a requirement a hydrogen peroxide generator, for the decontamination of interior room surfaces and equipment. The system will support forthcoming research activities within a model (mock) healthcare environment at its Porton Down site. The UKHSA intends to proceed with an open procedure to procure the equipment and associated services and this notice is to provide notification of the forthcoming invitation to tender. The specification is currently being prepared however is expected to include a hydrogen peroxide generator which is/has: • A standalone unit capable of being easily transported and designed to minimise any possible exposure of staff to the sterilant. • Capable of decontamination of rooms with volumes ranging from 5 to 225 m3. • Controllable from outside of the room being decontaminated. • Capable of measuring and recording the environmental conditions in the room (e.g. temperature and humidity). • Capable of data storage to provide a record of the cycle and parameters obtained. • A simple closed loop cycle including an aeration step to ensure all vapours are removed by the end of the process. • Circulation and aeration units as required by the technology. • An independent hydrogen peroxide monitor for leak detection and final safety check for safe entry to room after cycle completion. • Capability for users to modify the cycles. • Availability of hydrogen peroxide consumable for purchase in containers and volumes that can be used with the generator. Hydrogen peroxide consumables must have a shelf life of at least six (6) months from the date of delivery when ordered from the Supplier. • Capable of monitoring and recording the hydrogen peroxide concentration within the room being decontaminated. • Suitable for use in healthcare settings in the UK. • Compliant with BS EN 17272:2020+A1:2025. The equipment must be supplied inclusive of: • Delivery to UKHSA premises at Porton Down. • Commissioning of the equipment. • Comprehensive training, on the safe use of the equipment and cycle development, to UKHSA nominated staff. • Technical support for UKHSA staff for the duration of the Contract. • Routine servicing, in accordance with the regime set out by the original equipment manufacturer (OEM), for a minimum of two (2) years from the date of delivery (or commissioning if later) to UKHSA. Servicing to include all preventative maintenance and replacement of parts where such replacement is set out in OEM’s servicing regime. • Technical support for the duration of the Contract. To include breakdown labour costs and rapid on-site response where required. • Manufacturer’s warranty. This notice is for information only and the information contained herein, including information relating to the nature and scope of the requirement, the estimated value and dates, is indicative only and is neither exhaustive nor binding and the Authority reserves the right, at its absolute discretion, to amend it at the time of issue of any further notices or at any other time.

Improving health outcomes through vaccines is a priority for the UK Health Security Agency (UKHSA). We aim to use UKHSA's capabilities across the full vaccine pathway to facilitate innovation and support the development and deployment of safe and effective vaccines, ensure the reliable and timely procurement, storage and distribution of vaccines, and drive increased uptake among the population to reduce the burden of infectious disease. UKHSA published a Vaccine Prospectus in August 2026, which sets out the work that UKHSA and the wider health family do to sustain and grow the UK's world-leading role in immunisation. It details the scope of our programmes, our policy objectives, how we work with industry, and forthcoming opportunities to work with us. The publication can be accessed here: https://www.gov.uk/government/publications/vaccine-prospectus-national-immunisation-programme-and-vaccine-products

The key dates for this RFI are as follows: RFI Published: 28 August 2026 RFI Response: 11 September 2026 Should you have any questions or queries relating to this RFI, please use the Atamis portal’s messaging centre to direct your questions to us for a response. If a response is not received by the RFI response deadline this will have no impact on your ability to tender for the opportunity in the future. UKHSA will not enter into contracts on the basis of replies to this RFI.   Description of Scope of Requirements: The UK Health Security Agency (UKHSA) is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation's health secure. Background: The UKHSA Sequencing Laboratories in Bristol, Colindale, Manchester, and Porton Down offer nucleic acid sequencing services to support a variety of public health and clinical functions. These services currently include ongoing pathogen surveillance programmes, clinical metagenomics sequencing, and outbreak detection. As part of the UKHSA Pathogen Genomics Strategy and Pandemic Preparedness Programme, we are looking to maintain and expand the capacity and efficiency of our Genomics services. We therefore wish to explore available liquid handling robotics to support sequencing laboratory processing. Should you wish to respond to this Request for Information or require more information, please follow the link below: https://atamis-1928--prospend.vf.force.com/apex/CS_ContractPage?filters=&page=1&Preview=Yes&searchStr=&SearchType=Projects&sortStr=Alphabetical&uid=a07Pz00001uBE2zIAG&sfdcIFrameOrigin=https%3A%2F%2Fatamis-1928.lightning.force.com

The key dates for this RFI are as follows: RFI Published: 28 August 2026 RFI Response: 11 September 2026 Should you have any questions or queries relating to this RFI, please use the Atamis portal's messaging centre to direct your questions to us for a response. If a response is not received by the RFI response deadline this will have no impact on your ability to tender for the opportunity in the future. UKHSA will not enter into contracts on the basis of replies to this RFI.   Description of Scope of Requirements: The UK Health Security Agency (UKHSA) is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation's health secure. Background: The UKHSA Sequencing Laboratories in Bristol, Colindale, Manchester, and Porton Down offer nucleic acid sequencing services to support a variety of public health and clinical functions. These services currently include ongoing pathogen surveillance programmes, clinical metagenomics sequencing, and outbreak detection. As part of the UKHSA Pathogen Genomics Strategy and Pandemic Preparedness Programme, we are looking to maintain and expand the capacity and efficiency of our Genomics services. We therefore wish to explore available liquid handling robotics to support sequencing laboratory processing. Should you wish to respond to this Request for Information or require more information, please follow the link below: https://atamis-1928--prospend.vf.force.com/apex/CS_ContractPage?filters=&page=1&Preview=Yes&searchStr=&SearchType=Projects&sortStr=Alphabetical&uid=a07Pz00001uBE2zIAG&sfdcIFrameOrigin=https://atamis-1928.lightning.force.com

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Doxycycline 10 pack through this Request for Information (RFI), in accordance with the Procurement Act 2023.

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Pralidoxime Chloride through this Request for Information (RFI), in accordance with the Procurement Act 2023. Suppliers wishing to be considered for inclusion in this procurement exercise must confirm their participation by the stated deadline. Suppliers who do not participate will not be included in the procurement process or considered for subsequent stages.

Provision of immunisations which protect against, diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b (Hib) and hepatitis B programmes for supply from 2028. Contract length is still under review but may be required up to a period of 3 years with the option to extend for a period or periods up to an additional 24 months. The opportunity will be split into lots.

Pipette maintenance, calibration and repair service for the pipettes in circulation within UKHSA Laboratories.

The UK Health Security Agency (UKHSA) is preparing to engage the market on a major construction opportunity in Harlow, Essex. The opportunity sits within the UK Health Security Campus Programme: a once-in-a-generation investment to create a modern, purpose-built national health security and biosecurity campus. The new campus will bring together UKHSA’s specialist scientific facilities from Porton Down and Colindale and its London headquarters functions onto a single integrated site in Harlow. The campus is intended to provide modern laboratories, office accommodation and supporting infrastructure to strengthen the UK’s ability to detect, assess and respond to serious public health and biosecurity threats. This Preliminary Market Engagement Notice relates to the procurement of a Tier 1 construction contractor for the design and build of the campus facilities and infrastructure outside the separately managed high-containment laboratory building. In practical terms, the potential requirement is expected to include a new science and headquarters building, medium-containment laboratory capability, office accommodation, energy centre, logistics and support facilities, arrivals and education facilities, external works, utilities, site infrastructure and associated campus-wide integration. The separately managed high-containment laboratory building, which will contain the most specialist Containment Level 4 capability, will be delivered through a separate agreement and is not the focus of this engagement activity. UKHSA is using this engagement to test and develop the core commercial considerations, such as; whether the remaining campus works should ideally be delivered through a single Tier 1 design and build model, or whether alternative delivery models would improve deliverability, competition and value for money. The potential requirement would include: • a new science and headquarters building providing modern laboratory, technical and office accommodation for around 2400 FTE ; • containment Level 2 and Containment Level 3 laboratory areas and associated technical environments; • office space and shared facilities to support the relocation and co-location of UKHSA staff; • logistics, warehousing, support and campus operations facilities; • arrivals, reception, security, education, training and outreach facilities; • site-wide infrastructure, a dedicated energy centre, utilities, external works, access, parking and enabling works; • coordination with the separately managed high-containment laboratory project and other programme workstreams; • construction logistics, phasing, mobilisation, commissioning support and handover planning; • health, safety, environmental, quality, security and regulatory coordination requirements; • sustainability, carbon reduction, energy efficiency, materials reuse and social value outcomes. The opportunity is part of a wider programme targeting full campus operational readiness by 2038. Key programme activities include advanced works and main construction during the late 2020s and early 2030s, followed by transition, commissioning, validation and relocation activity through the mid-to-late 2030s. Further detail on the programme timings will be available via the engagement process and may be subject to change as work progresses. The final scope, procurement route, contract model, packaging strategy, value and timetable remain subject to approval and are likely to change following market engagement and further project development. The estimated costs within this notice represent the anticipated cost of the construction work associated with this opportunity. Through the market engagement process, the Agency will be able to provide additional detail on expected value vs potential value. This notice is for preliminary market engagement only. It is not a call for competition and does not commit UKHSA to commence a procurement or award a contract. Related professional services opportunity UKHSA is also progressing related professional services procurement activity to support the wider UK Health Security Campus Programme. This activity is expected to support the development, assurance, design, commercial, technical and delivery readiness of the programme. The professional services opportunity and this preliminary market engagement for the proposed Harlow science, headquarters and supporting campus infrastructure works are separate but related elements of the wider programme. Suppliers should note that the professional services activity is intended to support the development and delivery of the programme, while this notice relates to market engagement with organisations interested in the future construction delivery opportunity. UKHSA is referencing the related professional services activity in this notice to provide market context and to help suppliers understand the broader programme landscape. Interested suppliers should review any separately published notices for the professional services opportunity where relevant.

The key dates for this RFI are as follows: RFI Published: 30th June 2026 RFI Response: 14th July 2026 Should you have any questions or queries relating to this RFI, please use the Atamis portal's messaging centre to direct your questions to us for a response. If a response is not received by the RFI response deadline this will have no impact on your ability to tender for the opportunity in the future. UKHSA will not enter into contracts on the basis of replies to this RFI.   Description of Scope of Requirements: The UK Health Security Agency (UKHSA) is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation's health secure. Background: UKHSA is seeking to engage with the market to better understand supplier capability for the provision of lyophilisation (freeze-drying) services for X-ray irradiated pathogens to provide greater resilience and flexibility across use cases as part of UKHSA's Pandemic Preparedness strategy. UKHSA requires support in developing optimal formulations and lyophilisation processes to ensure that irradiated, inactivated pathogens can be safely stored, handled, and distributed for diagnostic use and pandemic preparedness. Lyophilisation is required to enhance the long-term stability and usability of these materials, supporting strategic resilience and response capabilities. Requirements: We need the supplier to have: • Ability to handle irradiated, inactive viral and bacterial material in liquid medium • Ability to develop and optimise lyophilisation protocols including assessment of different stabilisation matrices • Appropriate quality system in place (at least ISO 9001) to ensure consistency and traceability • Provide product quality control (QC) testing of final product, including thermal stability and absence of contaminants. • Overall aim is to lyophilise up to 20 pathogens over the next 4 years o Estimated vial volume for lyophilisation is 0.3mL - 2mL o Estimated batch size for lyophilisation is 6 - 100mL o Estimated number of batches per year is 5 Should you wish to respond to this Request for Information, please complete the response questionnaire which is found at the following link: https://atamis-1928--prospend.vf.force.com/apex/CS_ContractPage?filters=&page=1&Preview=Yes&searchStr=&SearchType=Projects&sortStr=Alphabetical&uid=a07Pz00001jEyqdIAC&sfdcIFrameOrigin=https://atamis-1928.lightning.force.com

The purpose of this document is to enhance the Authority’s understanding of the marketplace and its options for sourcing for a potential future requirement. The issuance of this request for information (RFI) does not constitute a sourcing exercise nor will the Authority pay any costs incurred in the preparation of a response to this RFI. The UK Health Security Agency’s (UKHSA) key objectives for this RFI are: understand the ability of the marketplace to fulfil its requirements; refine the scope of the requirements to best align to the marketplace; and inform the Authority’s chosen route to market to best enable competition The key dates for this RFI are as follows: RFI Published: 30th June 2026 RFI Response: 14th July 2026 Should you have any questions or queries relating to this RFI, please use the Atamis portal’s messaging centre to direct your questions to us for a response. If a response is not received by the RFI response deadline this will have no impact on your ability to tender for the opportunity in the future. UKHSA will not enter into contracts on the basis of replies to this RFI.   Description of Scope of Requirements: The UK Health Security Agency (UKHSA) is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation's health secure. Background: UKHSA is seeking to engage with the market to better understand supplier capability for the provision of lyophilisation (freeze-drying) services for X-ray irradiated pathogens to provide greater resilience and flexibility across use cases as part of UKHSA’s Pandemic Preparedness strategy. UKHSA requires support in developing optimal formulations and lyophilisation processes to ensure that irradiated, inactivated pathogens can be safely stored, handled, and distributed for diagnostic use and pandemic preparedness. Lyophilisation is required to enhance the long-term stability and usability of these materials, supporting strategic resilience and response capabilities. Requirements: We need the supplier to have: • Ability to handle irradiated, inactive viral and bacterial material in liquid medium • Ability to develop and optimise lyophilisation protocols including assessment of different stabilisation matrices • Appropriate quality system in place (at least ISO 9001) to ensure consistency and traceability • Provide product quality control (QC) testing of final product, including thermal stability and absence of contaminants. • Overall aim is to lyophilise up to 20 pathogens over the next 4 years o Estimated vial volume for lyophilisation is 0.3mL – 2mL o Estimated batch size for lyophilisation is 6 – 100mL o Estimated number of batches per year is 5 Should you wish to respond to this Request for Information, please complete the response questionnaire which is found at the following link: https://atamis-1928--prospend.vf.force.com/apex/CS_ContractPage?filters=&page=1&Preview=Yes&searchStr=&SearchType=Projects&sortStr=Alphabetical&uid=a07Pz00001jEyqdIAC&sfdcIFrameOrigin=https%3A%2F%2Fatamis-1928.lightning.force.com

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Botulinum Antitoxin Heptavalent (HBAT) through this Request for Information (RFI), in accordance with the Procurement Act 2023. The purpose of this exercise is to gather information on available products, supplier capability, and market conditions to inform a potential future procurement.

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Prussian Blue through this Request for Information (RFI), in accordance with the Procurement Act 2023. The purpose of this exercise is to gather information on available products, supplier capability, and market conditions to inform a potential future procurement.

The UK Health Security Agency (UKHSA) wishes to establish contracts for the provision of measles, mumps and rubella (MMR) vaccine